Efficacy and tolerability of everolimus [Xience V] vs sirolimus [Cypher] drug eluting stents for the prevention of coronary artery restenosis and cardiovascular events in patients undergoing percutaneous coronary interventions: APPENDIX-AMI

Trial Profile

Efficacy and tolerability of everolimus [Xience V] vs sirolimus [Cypher] drug eluting stents for the prevention of coronary artery restenosis and cardiovascular events in patients undergoing percutaneous coronary interventions: APPENDIX-AMI

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2011

At a glance

  • Drugs Everolimus (Primary) ; Sirolimus (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms APPENDIX-AMI
  • Most Recent Events

    • 13 Dec 2011 New source identified and integrated (Netherlands Trial Register).
    • 13 Dec 2011 Planned end date (Jun 2012) added as reported by Netherlands Trial Register record.
    • 13 Dec 2011 Planned number of patients 2000, lead trial centre, actual initiation date 1 Dec 2007 added as reported by Netherlands Trial Register record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top